Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO103 Vaccine in Multiple Myeloma
NCT03042793Phase 1Completed
- Start
- Feb 2017
- Primary completion
- May 2020
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IO103 + Montanide in multiple myeloma (MM). Primary endpoint: Incidence of toxicity at 12 months. Started Feb 2017; status: completed.
02
Drugs
IO103 + Montanide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03042793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042793.